甘李药业，解聘财务负责人兼副总经理

Core Viewpoint - Ganli Pharmaceutical announced the dismissal of its financial officer and vice president, Sun Cheng, due to the strategic need for global upgrades in innovative drug research and marketing, effective immediately upon board approval [1][6]. Group 1: Personnel Changes - Sun Cheng's departure means he will no longer hold any position within the company, with his original term set to expire on May 20, 2028 [1][6]. - The board has appointed Ms. Zhou Li to act as the financial officer following Sun Cheng's departure [5][10]. Group 2: Financial Performance - For the third quarter of 2025, Ganli Pharmaceutical reported a revenue of 3.05 billion yuan, representing a year-on-year increase of 35.7% [5][10]. - The net profit attributable to shareholders reached 818 million yuan, up 61.3% year-on-year, while the net profit excluding non-recurring items was 692 million yuan, reflecting a significant increase of 122.8% [5][10]. - The growth in revenue was driven by increased sales of domestic insulin preparations, and the company has strengthened its market share internationally through improved product quality and customer service [5][10].